| 产品编号 |
产品名称 |
产品包装 |
产品价格 |
| S1961-200mg |
Hydroxyurea (DNA Synthesis抑制剂) |
200mg |
61.00元 |
化学信息：
|
化学名
|
1-hydroxyurea
|
|
|
简称
|
Hydroxyurea
|
|
别名
|
Hydroxycarbamide, Hydrea,Hydroxycarbamid, Oncocarbide
|
|
中文名
|
羟基脲
|
|
化学式
|
CH4N2O2
|
|
分子量
|
76.05
|
|
CAS号
|
127-07-1
|
|
纯度
|
98%
|
|
溶剂/溶解度
|
Water 15mg/ml; DMSO 15mg/ml; Ethanol <1mg/ml
|
|
溶液配制
|
每5mg加入6.57ml DMSO，或每0.76mg加入1ml DMSO，配制成10mM溶液。S1961-10mM用DMSO配制。
|
生物信息：
|
产品描述
|
Hydroxyurea是一种DNA合成抑制剂，通过抑制核苷二磷酸还原酶而抑制DNA合成，可以使细胞周期阻滞在S期。
|
|
信号通路
|
DNA Damage
|
|
靶点
|
ribonucleoside diphosphate reductase
|
|
IC50
|
－
|
|
体外研究
|
Hydroxyurea is a DNA synthesis inhibitor, and can inhibit HIV-1 replication. In vitro experiments have shown that the 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC is 0.4mM. Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes. Hydroxyurea has been shown to sensitize didanosine-resistant mutants. Hydroxyurea has demonstrated activity in the treatment of sickle cell anemia by increasing the production of fetal hemoglobin, which reduces hemolysis in patients with this disease. Hydroxyurea exerts its cytostatic effect through inhibition of ribonucleotide reductase—the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. As a result, cellular division is arrested in the S phase.
|
|
体内研究
|
N/A
|
|
临床实验
|
N/A
|
|
特征
|
N/A
|
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
|
酶活性检测实验
|
|
方法
|
N/A
|
|
细胞实验
|
|
细胞系
|
Erythroid cells
|
|
浓度
|
30μM
|
|
处理时间
|
96h
|
|
方法
|
Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5mg/kg/day for 5 days/week with escalation to a maximum of 10mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro. Treatment of cells performs in primary culture with 30μM hydroxyurea for 96 hours.
|
|
动物实验
|
|
动物模型
|
Female athymic (nu/nu) nude mice (used for xenograft model)
|
|
配制
|
saline
|
|
剂量
|
1500mg/kg
|
|
给药方式
|
i.p.
|
参考文献：
1. Lori F, et al. Clin Infect Dis. 2000, 30 Suppl 2:S193-7.
2. Zala C, et al. Clin Infect Dis. 2000, Suppl 2:S143-50.
3. Boucher PD, et al. Gene Ther. 2002, 9(15):1023-30.
4. Watanapokasin Y, et al. Exp Hematol. 2005, 33(12):1486-92.
包装清单：
|
产品编号
|
产品名称
|
包装
|
|
S1961-10mM
|
Hydroxyurea (DNA Synthesis抑制剂)
|
10mM×1ml
|
|
S1961-200mg
|
Hydroxyurea (DNA Synthesis抑制剂)
|
200mg
|
|
S1961-1g
|
Hydroxyurea (DNA Synthesis抑制剂)
|
1g
|
|
S1961-5g
|
Hydroxyurea (DNA Synthesis抑制剂)
|
5g
|
|
—
|
说明书
|
1份
|
保存条件：
-20℃保存，至少一年有效。200mg、1g和5g包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：
本产品对人体有毒，操作时请特别小心，并注意有效防护以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。